The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced cancers. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, in solid tumors and hematological malignancies. He received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practiced medicine prior to his career in the biopharmaceutical industry.Ĭyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology.
In addition, he serves as an advisor, SAB member and independent consultant for numerous biotech and investment companies.
He is currently a Board Member of LifeSci Acquisition Corp, Mereo Biopharma and Enlivex. Schwartz was CMO at Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma. During the past decade he has served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc., which was acquired for $2.7bn by Merck & Co. Schwartz has wide-ranging experience as a drug development expert in pharmaceutical and biotechnology industries primarily in oncology, hematology, and rare diseases. The clinical development plans and Cyclacel’s experienced management team provide a strong basis for success in the Company’s programs.”ĭr. These two internally discovered molecules have competitive product profiles and address oncology indications with large unmet medical needs. “After evaluating the scientific and clinical merits of Cyclacel’s medicines, I am enthusiastic of the prospects of fadraciclib and CYC140. “I am excited to join the Board at an important moment in the Company’s history,” said Dr. “Brian’s experience in all development stages of innovative medicines for cancer will be very valuable as we advance our business strategy."
His extensive clinical and product development experience further adds to the strength of our Board and will support management’s efforts to build shareholder value," said Christopher Henney, Ph.D., Chairman of the Board of Cyclacel. "We are very pleased to have Brian join the Board of Directors of Cyclacel. (NASDAQ: CYCC, NASDAQ: CYCCP "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Brian Schwartz, M.D., to its Board of Directors. 21, 2020 (GLOBE NEWSWIRE) - Cyclacel Pharmaceuticals, Inc. Together, we thank the community for understanding during this unusual and challenging time.Former CMO & Head of R&D of ArQule joins the BoardīERKELEY HEIGHTS, N.J., Dec. Otherwise, funerals may be viewed live and recorded on chapel websites. Metro Detroit’s Jewish funeral homes have agreed that families should follow the directive of Centers for Disease Control and restrict the size of gatherings to no more than 25.įor now, in-person funeral attendance will be limited to only immediate family. He is predeceased by his sons Michael and Jerry, and his siblings David Schwartz, Joseph Schwartz, Hy Schwartz, Lillian Feldman, and Evelyn Levenson, as well as his parents, Sam and Sadie Schwartz.Ī hard worker who served his country and community, he is also remembered with love by many nieces, nephews, cousins and their families, as well as friends from Alma, Metro Detroit and beyond. Adored great-grandfather of Hannah and Miles Schwartz, Madeline and Mikayla Wald, and Jonah and Ethan Lederman.
Laura Pincus), Andrea (Dan) Wald, Karen Schwartz (Daniel Lederman), Steven Schwartz (fiancee Gehang Zhou), Eric (Morielle) Hoffman, and Alex (Natasha) Hoffman. Survived as well by his daughter Sue (Jeff) Hoffman, daughter-in-law Debbie Schwartz, and his sister Helen Grubner. On Wednesday, 16 December 2020 at 11:00 AMĬlick to watch a video of the recorded service.īeloved husband of Pauline Schwartz for 74 years. Harry Schwartz, 98, of Sarasota, Florida, formerly of Farmington Hills, Michigan, died after sunset on 10 December 2020.
0 kommentar(er)
